Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20510519 | 1.00 | FOLH1 (0.68) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL15844493 | 1.00 | FOLH1 (0.68) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL25418512 | 0.99 | FOLH1 (0.67) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL31314039 | 0.99 | FOLH1 (0.67) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL9631698 | 0.91 | SLC1A3 (0.59) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL20842458 | 0.91 | FOLH1 (0.61) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL19155742 | 0.88 | FOLH1 (0.66) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL20099440 | 0.85 | HTT (0.57) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL12831893 | 0.84 | FOLH1 (0.57) | FOLH1HTTMMP2MMP9TGM2 | |
| SCHEMBL21032263 | 0.83 | FOLH1 (0.60) | FOLH1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025080572-A1 | LIVER ASIALOGLYCOPROTEIN RECEPTOR TARGETED LIPID AND USES THEREOF | AVANTI POLAR LIPIDS, LLC (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4219718-A2 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-3608406-B1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2022-10-13 | — | — | US | disclosed |
| EP-0282042-B1 | Fusion proteins and their purification | HOFFMANN LA ROCHE (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5310663-A | Affinity peptides | HOFFMAN-LA ROCHE INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5284933-A | Affinity peptides | HOFFMANN-LA ROCHE INC. (US) | 1994-02-08 | — | — | US | disclosed |
| US-5238836-A | Genetic engineering; isolated DNA sequences | HOFFMANN-LA ROCHE INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0283829-B1 | PLASMODIUM FALCIPARUM MEROZOITE ANTIGEN PEPTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-08-04 | — | — | EP | disclosed |
| EP-0253303-B1 | METAL CHELATING RESINS | F. HOFFMANN-LA ROCHE AG (CH) | 1992-06-03 | — | — | EP | disclosed |
| US-5047513-A | Metal chelate resins | HOFFMANN-LA ROCHE INC. (US) | 1991-09-10 | — | — | US | disclosed |
| US-4877830-A | Metal chelate resins | HOFFMANN-LA ROCHE INC. (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0283829-A1 | Plasmodium falciparum merozoite antigen peptides | F. HOFFMANN-LA ROCHE AG (CH) | 1988-09-28 | — | — | EP | disclosed |
| EP-0282042-A2 | Fusion proteins and their purification | F. HOFFMANN-LA ROCHE AG (CH) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | FOLH1 410/4885HTT 817/4885MMP2 3418/4885 |
| US-20220324900-A1 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | TEK, PLIN3, FABP3 | FOLH1 2357/4885HTT 1170/4885MMP2 1388/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | FOLH1 862/4885HTT 144/4885MMP2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.